Cordlife Group Limited (CLIFF)
USD 0.12
(-8.61%)
USD 0.12
(-8.61%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 8.55 Million SGD | -6.72% |
| 2022 | 9.33 Million USD | 74.57% |
| 2021 | 10.78 Million SGD | 8.89% |
| 2020 | 12.03 Million SGD | 990.15% |
| 2019 | 12.72 Million SGD | 113.5% |
| 2018 | -3.26 Million SGD | -144.25% |
| 2017 | 7.38 Million SGD | 147.19% |
| 2016 | 3.21 Million SGD | -14.9% |
| 2015 | 3.5 Million SGD | -30.52% |
| 2014 | 5.05 Million SGD | -41.04% |
| 2013 | 8.56 Million SGD | -32.24% |
| 2012 | 12.64 Million SGD | 49.37% |
| 2011 | 8.46 Million SGD | -19.9% |
| 2010 | 10.56 Million SGD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q4 | 694 Thousand USD | 210.56% |
| 2023 Q1 | 989.23 Thousand SGD | -54.5% |
| 2023 FY | - SGD | -6.72% |
| 2023 Q2 | 2.62 Million USD | 164.95% |
| 2023 Q3 | 223.46 Thousand SGD | -91.47% |
| 2022 Q1 | 999.4 Thousand SGD | -76.14% |
| 2022 Q2 | 2.59 Million USD | 159.66% |
| 2022 Q3 | 777.05 Thousand SGD | -70.06% |
| 2022 FY | - USD | 74.57% |
| 2022 Q4 | 2.17 Million USD | 179.78% |
| 2021 Q4 | 4.18 Million SGD | 167.88% |
| 2021 Q3 | 1.56 Million SGD | 236.58% |
| 2021 FY | - SGD | 8.89% |
| 2021 Q1 | 1.19 Million SGD | 176.78% |
| 2021 Q2 | -1.14 Million SGD | -195.78% |
| 2020 Q1 | -57.69 Thousand SGD | -100.94% |
| 2020 Q4 | -1.55 Million SGD | -164.74% |
| 2020 FY | - SGD | 990.15% |
| 2020 Q3 | 2.4 Million SGD | 544.54% |
| 2020 Q2 | -541 Thousand SGD | -837.69% |
| 2019 Q1 | 3.61 Million SGD | 417.94% |
| 2019 FY | - SGD | 113.5% |
| 2019 Q4 | 6.13 Million SGD | 136.9% |
| 2019 Q3 | 2.59 Million SGD | 99.31% |
| 2019 Q2 | 1.3 Million SGD | -64.04% |
| 2018 Q3 | 1.55 Million SGD | -14.07% |
| 2018 Q2 | 1.8 Million SGD | -9.16% |
| 2018 Q4 | -1.13 Million SGD | -173.31% |
| 2018 FY | - SGD | -144.25% |
| 2018 Q1 | 1.98 Million SGD | 5.64% |
| 2017 Q2 | 1.58 Million SGD | 261.5% |
| 2017 Q3 | 1.7 Million SGD | 7.62% |
| 2017 FY | - SGD | 147.19% |
| 2017 Q1 | 439 Thousand SGD | -69.39% |
| 2017 Q4 | 1.88 Million SGD | 10.13% |
| 2016 Q4 | 1.43 Million SGD | -11.43% |
| 2016 Q2 | -682 Thousand SGD | -423.22% |
| 2016 FY | - SGD | -14.9% |
| 2016 Q1 | 211 Thousand SGD | 117.45% |
| 2016 Q3 | 1.61 Million SGD | 337.39% |
| 2015 Q1 | 9.57 Million SGD | 91.37% |
| 2015 Q4 | -1.2 Million SGD | -109.36% |
| 2015 Q3 | 12.91 Million SGD | 450.21% |
| 2015 Q2 | 2.34 Million SGD | -75.48% |
| 2015 FY | - SGD | -30.52% |
| 2014 FY | - SGD | -41.04% |
| 2014 Q4 | 5 Million SGD | 136.1% |
| 2014 Q3 | 2.11 Million SGD | -33.41% |
| 2014 Q2 | 3.18 Million SGD | 16.34% |
| 2014 Q1 | 2.73 Million SGD | 2.32% |
| 2013 Q1 | 1.62 Million SGD | -52.81% |
| 2013 FY | - SGD | -32.24% |
| 2013 Q3 | -25 Thousand SGD | -100.6% |
| 2013 Q2 | 4.15 Million SGD | 156.35% |
| 2013 Q4 | 2.67 Million SGD | 10792.0% |
| 2012 Q1 | 1.21 Million SGD | -47.9% |
| 2012 FY | - SGD | 49.37% |
| 2012 Q2 | 2.61 Million SGD | 115.73% |
| 2012 Q3 | 3.42 Million SGD | 30.74% |
| 2012 Q4 | 3.43 Million SGD | 0.38% |
| 2011 Q4 | 2.33 Million SGD | 41.56% |
| 2011 Q2 | 2.87 Million SGD | 28.62% |
| 2011 Q1 | 2.23 Million SGD | 0.0% |
| 2011 FY | - SGD | -19.9% |
| 2011 Q3 | 1.64 Million SGD | -42.69% |
| 2010 FY | - SGD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Bio Medica Corporation | -1.16 Million USD | 835.684% |
| Arrayit Corporation | -3.07 Million USD | 378.018% |
| Atlantic International Corp. | -5.38 Million USD | 258.751% |
| Biocept, Inc. | -30.24 Million USD | 128.293% |
| Bioqual, Inc. | 3.03 Million USD | -182.168% |
| CardioGenics Holdings Inc | -757.37 Thousand USD | 1229.691% |
| DermTech, Inc. | -97.89 Million USD | 108.74% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.91 Billion USD | 99.706% |
| HTG Molecular Diagnostics, Inc. | -20.24 Million USD | 142.268% |
| iMD Companies, Inc. | -154.65 Thousand USD | 5632.171% |
| IDenta Corp. | 71.58 Thousand USD | -11851.891% |
| Interpace Biosciences, Inc. | 3.83 Million USD | -122.987% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | -22014.241% |
| InVitro International | 6680.00 USD | -127983.832% |
| Lumos Diagnostics Holdings Limited | -5.43 Million USD | 257.395% |
| Many Bright Ideas Technologies Inc. | -12.13 Thousand USD | 70612.609% |
| Medical Imaging Corp. | -896.74 Thousand USD | 1054.121% |
| NovelStem International Corp. | -3.78 Million USD | 326.002% |
| Optigenex Inc. | -1.18 Million USD | 820.976% |
| PharmChem, Inc. | 1.05 Million USD | -711.911% |
| Proteome Sciences plc | -1.13 Million USD | 852.507% |
| Response Genetics, Inc | -19.66 Million USD | 143.507% |
| Rennova Health, Inc. | -234.81 Thousand USD | 3743.72% |
| RushNet, Inc. | -614.85 Thousand USD | 1491.554% |
| ScreenPro Security Inc. | -3.43 Million USD | 349.091% |
| Stella Diagnostics Inc. | -5.7 Million USD | 249.91% |
| StageZero Life Sciences Ltd. | -10.27 Million USD | 183.309% |
| Todos Medical Ltd. | -9.39 Million USD | 191.079% |